Today, Truveta kicks off Truveta Symposium, a unique event bringing together leaders from health systems, life sciences, and the government to collaborate on health research with real-world data, embracing generative AI to transform healthcare, and improving patient care and outcomes for all.
Key agenda items and speakers include:
Our inspiration, the value of trust, and learning together
- Terry Myerson, CEO and co-founder, Truveta
The transformative role of real-world data to democratize care
- Aida Habtezion, MD, MSC, FRCPC, AGAF, chief medical officer & head of worldwide medical & safety, Pfizer Inc.
- Rod Hochman, MD, CEO, Providence
Discordance in diagnosis time among patients with CKD: The effect of the CKD-EPI creatinine equation
- Charlotte Baker, DrPH, MPH, director of epidemiology, Truveta
Lessons learned using Truveta’s large language models to extract seizure frequency from unstructured data
- Sean Stern, director of health economics and outcomes research, SK Life Science, Inc.
Modernizing safety surveillance: Shared learnings across drugs and devices
- Patrick Caubel, MD, chief safety officer, Pfizer Inc.
- Michael Jaff, DO, FACC, chief medical officer, vice president, clinical affairs, technology & innovation, peripheral interventions, Boston Scientific
- Bram Zuckerman, MD, director of the office of cardiovascular devices, Food & Drug Administration (FDA) Center for Devices and Radiological Health
Empowering researchers to deliver high-quality, real-world evidence with the most complete, timely, and clean EHR data
- Michael Simonov, MD, vice president, Product, Truveta
Contemporary treatment strategies in patients hospitalized for heart failure
- Jimmy Zheng, MD, MS, Stanford University School of Medicine
Factors associated with discontinuation and reinitiation of GLP-1 RA
- Tricia Rodriguez, PhD, MPH, principal applied scientist, Truveta
Using RWD to understand utilization and disparities of drug eluting stents for the treatment of femoropopliteal artery disease
- Abimbola Williams, senior manager, HEOR, research methodologies, Boston Scientific
Industry collaboration to improve TAVR care gaps with RWD
- Ty Gluckman, MD, MHA, FACC, FAHA, FASPC, medical director, center for cardiovascular analytics, research, and data science (CARDS), Providence Heart Institute, Providence
- Michael Mack, MD, chair cardiovascular service line, chairman of the board at Baylor Scott & White Research Institute and Heart Valve Collaboratory
- Pooja Sharma, senior vice president, marketing and strategy, transcatheter heart valves, Edwards Lifesciences
Innovating with generative AI
- Jay Nanduri, chief technical officer and co-founder, Truveta
Participating organizations include Abbott, Advocate Health, American Heart Association, Baylor Scott & White Health, Boehringer Ingelheim, Boston Scientific, Cardiovascular Research Foundation, Centers for Disease Control and Prevention (CDC), CommonSpirit Health, Dexcom, Duke University, Edwards Lifesciences, Eli Lilly, Food and Drug Administration (FDA) Center for Devices and Radiological Health, Fred Hutchinson Cancer Research Center, Hawaii Pacific Health, Heart Valve Collaboratory, Henry Ford Health, HonorHealth, Mathematica, National Cancer Institute Division of Cancer Epidemiology and Genetics, Northwell Health, Northwestern Medicine Feinberg School of Medicine, Pfizer, Providence, Regeneron, Reprieve Cardiovascular, Sanford Health, SK Life Science, Inc., Stanford University, Stryker, Texas Health Resources, Trinity Health, and University of Washington.
For more information, visit the Truveta Symposium page.